Nyrada (ASX:NYR) Extends Its Run as Xolatryp Enters a Phase II Test

Aditi Sarkar

04 August 2026 07:22 PM AEST

Nyrada (ASX:NYR) Extends Its Run as Xolatryp Enters a Phase II Test

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Nyrada shares gained 8.76% to AUD 0.745 and finished near the session high of AUD 0.750.
Nyrada moved the PROTECT-MI Phase IIa study towards enrolment across seven Australian hospitals, with the trial designed to assess safety and preliminary efficacy after myocardial infarction.
Volume reached 562,100 shares, while market capitalisation stood near AUD 184.08mn.
Patient recruitment, dosing, safety data and preliminary efficacy will shape the clinical outlook.

Nyrada (ASX:NYR) moved into focus after the shares rose 8.76% to AUD 0.745. The stock traded between AUD 0.690 and AUD 0.750, with 562,100 shares changing hands. The move renewed attention on the company’s latest clinical, regulatory or commercial development, while the one-year return of 132.81% shows the broader path has been very different across this group of emerging healthcare companies.

For a small healthcare or biotechnology company, a sharp daily gain can reflect a genuine milestone, renewed speculation or limited liquidity. The durability of the move will depend on execution, funding and measurable progress rather than the percentage change alone.

Company Overview

Nyrada develops small-molecule TRPC ion-channel inhibitors. Its lead programme, Xolatryp, is being studied for cardiovascular protection and other potential indications.

Latest Company Development

Nyrada moved the PROTECT-MI Phase IIa study towards enrolment across seven Australian hospitals, with the trial designed to assess safety and preliminary efficacy after myocardial infarction. The company also reported preclinical anti-tumour activity and received an AUD 2.455mn R&D tax rebate.

Share Price and Market Snapshot

NYR closed at AUD 0.745, up 8.76, after reaching AUD 0.750. The session low was AUD 0.690, while volume totalled 562,100 shares. The closing market value was approximately AUD 184.08mn. Over one year, the shares changed 132.81%, placing the latest move within a longer and often volatile trend.

What Investors May Watch Next

Patient recruitment, dosing, safety data and preliminary efficacy will shape the clinical outlook. The 132.81% one-year gain raises sensitivity to delays or results that do not meet expectations.

The next company announcement should help distinguish short-term trading momentum from a lasting change in expectations. For development-stage businesses, timelines, cash runway and external validation are as important as the headline catalyst.

Risks

The latest share-price gain may reverse if the catalyst does not translate into measurable progress.
Clinical studies, regulatory reviews or product development may be delayed or unsuccessful.
Commercial adoption and reimbursement may develop more slowly than expected.
Additional funding could dilute existing shareholders or place pressure on the balance sheet.
Low liquidity and broader market conditions may amplify share-price volatility.

FAQs

Q: Why did Nyrada shares attract attention?

A:NYR gained 8.76% to AUD 0.745 and traded near its session high of AUD 0.750.

Q: What is the latest development at Nyrada?

A:Nyrada moved the PROTECT-MI Phase IIa study towards enrolment across seven Australian hospitals, with the trial designed to assess safety and preliminary efficacy after myocardial infarction. The company also reported preclinical anti-tumour activity and received an AUD 2.455mn R&D tax rebate.

Q: What is Nyrada’s market capitalisation?

A:The company’s market capitalisation stood at approximately AUD 184.08mn at the stated closing price.

Q: What should shareholders watch next?

A:Patient recruitment, dosing, safety data and preliminary efficacy will shape the clinical outlook. The 132.81% one-year gain raises sensitivity to delays or results that do not meet expectations.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.